Methyprylon
Clinical data | |
---|---|
Trade names | Dimerin, Methyprylone, Noctan, Noludar |
Routes of administration | oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 60% |
Elimination half-life | 6-16 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C10H17NO2 |
Molar mass | 183.248 g/mol |
| |
(what is this?) (verify) |
Methyprylon (Noludar) is a sedative of the piperidinedione derivative family developed by Hoffmann-La Roche.[1] This medicine was used for treating insomnia, but is now rarely used as it has been replaced by newer drugs with fewer side effects, such as benzodiazepines.[2] Methyprylon was withdrawn from the US market in June 1989 and the Canadian market in September 1990. Some other trade names are Noctan and Dimerin.
Adverse effects
Side effects can include skin rash, fever, depression, ulcers or sores in mouth or throat, unusual bleeding or bruising, confusion, fast heartbeat, respiratory depression, swelling of feet or lower legs, dizziness, drowsiness, headache, double vision, clumsiness, constipation, diarrhea, nausea, vomiting, unusual weakness.[citation needed]
Pharmacokinetics
A study of single oral doses of 300 mg in healthy volunteers found that the zero-order absorption model fit the data best. Mean (+/- SD) values for the half-life (9.2 +/- 2.2 h), apparent clearance, (11.91 +/- 4.42 mL/h/kg) and apparent steady-state volume of distribution, (0.97 +/- 0.33 L/kg) were found.[3]
A case report found that the pharmacokinetics of methyprylon were not concentration dependent in an overdose case; explanations included saturation or inhibition of metabolic pathways. The generally accepted half-life for a therapeutic dose was not found appropriate in intoxicated patients and would underestimate the time required to reach a safe concentration of the drug.[4]
See also
References
- ↑
US patent 2680116, Frick, H. & Lutz, A. H., "Piperidiones and Process for the Manufacture thereof", issued 1954-06-01, assigned to Hoffmann-La Roche
WikiDoc Resources for Methyprylon
Articles
Most recent articles on Methyprylon
Most cited articles on Methyprylon
Media
Powerpoint slides on Methyprylon
Evidence Based Medicine
Clinical Trials
Ongoing Trials on Methyprylon at Clinical Trials.gov
Clinical Trials on Methyprylon at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Methyprylon
Books
News
Commentary
Definitions
Patient Resources / Community
Patient resources on Methyprylon
Discussion groups on Methyprylon
Patient Handouts on Methyprylon
Directions to Hospitals Treating Methyprylon
Risk calculators and risk factors for Methyprylon
Healthcare Provider Resources
Causes & Risk Factors for Methyprylon
Continuing Medical Education (CME)
International
Business
Experimental / Informatics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] == Overview ==
- ↑ PMID 16792 (PMID 16792)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 2866242 (PMID 2866242)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 1686463 (PMID 1686463)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
- Pages with script errors
- Pages with incomplete PMID references
- Articles with changed KEGG identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles with non-default infobox title
- Drugboxes which contain changes to verified fields
- All articles with unsourced statements
- Articles with unsourced statements from October 2011
- Articles with invalid date parameter in template
- Pages using div col with unknown parameters
- Drug
- Piperidines
- Lactams
- Ketones
- GABAA receptor positive allosteric modulators